NYSE · Healthcare
Teladoc Health, Inc. (TDOC)
As-reported financials and recent SEC filings for Teladoc Health, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.53B
Net income
$-200.3M
Net margin
-7.9%
Diluted EPS
$-1.14
ROE
-14.5%
P/E (TTM)
—
Market cap
$1.51B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.53B | $2.57B | $2.60B | $2.41B | $2.03B |
| Gross profit | — | — | — | $1.66B | $1.38B |
| Operating income | $-263.0M | $-1.02B | $-248.6M | $-13.65B | $-265.6M |
| Net income | $-200.3M | $-1.00B | $-220.4M | $-13.66B | $-428.8M |
| Diluted EPS | $-1.14 | $-5.87 | $-1.34 | $-84.60 | $-2.73 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G2026-06-22
View on EDGAR →42026-06-12
View on EDGAR →1442026-06-11
View on EDGAR →42026-06-04
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →1442026-06-03
View on EDGAR →Go deeper on TDOC
Search Teladoc Health, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.